Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Peplin Completes Enrollment In Phase-III Clinical Trials
Peplin has completed the enrolment of its two phase-III clinical trials, for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK). These phase-III clinical
Peplin has completed the enrolment of its two phase-III clinical trials, for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK). These phase-III clinical
Boehringer Ingelheim announced that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) for Viramune (nevirapine) in the treatment of patients with HIV.
Three new small-and-medium-sized enterprises (SMEs) – Syncom, Synvolux and InteRNA, have signed a partnership agreement with TI Pharma by participating in two new projects. These projects would focus
Sanofi-aventis has published the results of the five-year study of Lantus (insulin glargine injection) versus NPH insulin, on progression of retinopathy in patients with type 2 diabetes. The
Oxford BioMedica has received final comments following the FDA’s review of the phase-III TRIST study of TroVax in renal cancer, and the proposed clinical development outline. FDA acknowledged
McKesson has renewed its current distribution agreement to supply CVS with branded and generic drugs. Paul Julian, Executive Vice President and Group President, McKesson, said: “CVS’s decision to
Cardinal Health has renewed its distribution agreement with CVS Caremark, to supply pharmaceuticals to its national network of retail pharmacies through mid 2013. George Barrett, Vice Chairman of
French pharmaceutical company Sanofi-aventis has unveiled the results of the five-year study of Lantus (insulin glargine injection) versus NPH insulin, on progression of retinopathy in patients with type
Avanir has announced that the open label extension of the confirmatory phase III STAR trial is now fully enrolled. The primary objective of the study is to assess
Theraclone and the International AIDS Vaccine Initiative (IAVI) have expanded their HIV antibody discovery program. Under the terms of the agreement, Theraclone would receive additional funding from IAVI